AUS
NZ
UK
CA
USA
IND
Highlights
Scancell Holdings PLC (LON:SCLP) is listed on the FTSE AIM UK 50 INDEX, operating in the biotechnology sector
The company is conducting a phase II trial for its iSCIB1+ cancer immunotherapy for advanced melanoma
Plans to spin off its GlyMab antibody platform into a separate entity, Glymab Therapeutics
Scancell Holdings PLC (LON:SCLP), a biotechnology firm listed on the FTSE AIM UK 50 INDEX, operates in the field of cancer immunotherapy. The company is engaged in developing therapies that aim to activate the immune system to recognise and fight cancer cells more effectively. Its work spans clinical trials and research platforms aimed at tackling advanced melanoma and other cancers.
Development of Intradermal Immunotherapy
A new arm of a phase II trial has been initiated by Scancell Holdings PLC to study the effects of an updated delivery method of its immunotherapy, iSCIB1+. This arm, called Cohort 4, focuses on administering the therapy intradermally, which could support enhanced immune activation. The revised dosing schedule forms a key component of this approach, with the therapy being evaluated in combination with checkpoint inhibitors.
Trial Progress and Dosing Milestones
Cohort 4 commenced with the administration of treatment to the initial group of patients without reporting significant side effects. The open-label SCOPE trial is being conducted across multiple research centres and includes more than one treatment group. The therapy is designed to work with existing immunotherapies to amplify immune responses against melanoma cells.
Previous Data and Therapy Performance
In previous phases, iSCIB1+ was administered with immune checkpoint inhibitors including ipilimumab and nivolumab. Reports from one group within the trial showed sustained disease control and favorable treatment responses. The study continues to explore how this therapy performs across different patient groups and in conjunction with other immunotherapeutic agents.
Forthcoming Trial Updates
Scancell Holdings is preparing to release further clinical data in the near future. The first three cohorts are scheduled for data updates in July, while early indicators from Cohort 4 are expected before the close of the year. These updates may shed more light on the therapy’s ability to engage immune functions in advanced melanoma treatment.
Strategic Expansion of Antibody Research
Alongside immunotherapy trials, the company is advancing its GlyMab antibody platform. To better streamline its research operations, Scancell has outlined plans to establish Glymab Therapeutics as a separate entity. This spin-out strategy reflects a broader initiative to sharpen development focus amid evolving conditions within the biotech funding environment.
Sector Innovation and Pipeline Activity
Scancell’s current pipeline includes both clinical-stage treatments and preclinical platforms. By expanding its research into antibody technologies while progressing through later stages of immunotherapy trials, the company remains engaged in cancer-focused therapeutic development. These initiatives align with broader movements across the biotechnology space in pursuit of immunologically driven solutions.
Index Alignment and Market Presence
Scancell Holdings continues its research as part of the FTSE AIM UK 50 INDEX, a group comprising emerging firms within the UK’s alternative market. Its focus on immuno-oncology aligns with the sector’s commitment to scientific innovation and disease-specific advancements.
Clinical Goals and Forward Development
The company’s dual-track strategy across immunotherapy trials and antibody research reflects its position within the UK biotechnology sector. With multiple programs underway, Scancell Holdings PLC remains actively involved in the development of disease-targeted platforms. The SCOPE trial and its forthcoming updates may provide further context on the company’s approach to clinical progression and sector engagement.
